The heterogeneity of pathomechanisms leading to systemic lupus erythematosus (SLE) might contribute to between-patient variations in treatment response. A new, longitudinal transcriptome analysis has identified molecularly distinct subgroups of SLE that correlate with disease activity; use of such disease classifiers might facilitate the development of stratified treatment recommendations.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Banchereau, R. et al. Personalized immunomonitoring uncovers molecular networks that stratify lupus patients. Cell 165, 551–565 (2016).
Migliorini, A. & Anders, H.-J. A novel pathogenetic concept — antiviral immunity in lupus nephritis. Nat. Rev. Nephrol. 8, 183–189 (2012).
Chung, S. A. et al. Lupus nephritis susceptibility loci in women with systemic lupus erythematosus. J. Am. Soc. Nephrol. 25, 2859–2870 (2014).
Anders, H. J. & Fogo, A. B. Immunopathology of lupus nephritis. Semin. Immunopathol. 36, 443–459 (2014).
Anders, H. J., Jayne, D. R. & Rovin, B. H. Hurdles to the introduction of new therapies for immune-mediated kidney diseases. Nat. Rev. Nephrol. 12, 205–216 (2016).
Biankin, A. V., Piantadosi, S. & Hollingsworth, S. J. Patient-centric trials for therapeutic development in precision oncology. Nature 526, 361–370 (2015).
Ju, W. et al. Tissue transcriptome-driven identification of epidermal growth factor as a chronic kidney disease biomarker. Sci. Transl. Med. 7, 316ra193 (2015).
Tuttle, K. et al. Baricitinib in diabetic kidney disease: results from a phase 2, multicenter, randomized, double-blind, placebo-controlled study. Scientific Session http://www.abstractsonline.com/pp8/#!/3699/presentation/12757 (2015).
Jacobi, A. M. et al. HLA-DRhigh/CD27high plasmablasts indicate active disease in patients with systemic lupus erythematosus. Ann. Rheum. Dis. 69, 305–308 (2010).
Acknowledgements
Critical review of the manuscript by Heather K. Ascani, University of Michigan, before submission, is greatly appreciated. H.-J.A. is supported by the European Union's Horizon 2020 research and innovation program under grant agreement No. 668036 (RELENT). M.K. is supported by NIH U54 DK083912, Nephrotic Syndrome Rare Disease Clinical Research Network II, and NIH P30 DK081943 George M. O'Brien Kidney Research Core Center at the University of Michigan.
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Competing interests
The authors declare no competing financial interests.
PowerPoint slides
Rights and permissions
About this article
Cite this article
Anders, HJ., Kretzler, M. Personalized immunomonitoring in lupus and lupus nephritis. Nat Rev Nephrol 12, 320–321 (2016). https://doi.org/10.1038/nrneph.2016.69
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrneph.2016.69
